Christie Ballantyne

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, Texas, USA
    Am J Cardiol 96:14K-19K; discussion 34K-35K. 2005
  2. pmc LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD
    James McKenney
    National Clinic Research, Inc, Richmond, Virginia, USA
    MedGenMed 7:3. 2005
  3. pmc A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study
    L Maria Belalcazar
    Department of Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    Diabetes Care 33:2297-303. 2010
  4. doi request reprint Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study
    Christie M Ballantyne
    Department of Medicine, Baylor College of Medicine and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX, USA Electronic address
    Atherosclerosis 232:86-93. 2014
  5. doi request reprint Icosapent ethyl for the treatment of hypertriglyceridemia
    Christie M Ballantyne
    Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, 6565 Fannin, M S A 601, Houston, TX 77030, USA
    Expert Opin Pharmacother 14:1409-16. 2013
  6. ncbi request reprint Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia
    Christie Ballantyne
    Section of Atherosclerosis, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, 6565 Fannin, MS A601, Houston, TX 77030, USA
    J Clin Lipidol 6:235-43. 2012
  7. ncbi request reprint Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)
    Christie M Ballantyne
    Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
    Am J Cardiol 110:984-92. 2012
  8. pmc Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities study
    Smita I Negi
    Section of Cardiovascular Research, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX, USA
    Diabetes Care 35:1513-8. 2012
  9. doi request reprint Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study
    Christie M Ballantyne
    Baylor College of Medicine, and Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, USA
    Am Heart J 163:515-21, 521.e1-3. 2012
  10. pmc Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis
    Suet Nee Chen
    Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center and Texas Heart Institute, Houston, TX, USA
    BMC Med Genet 10:111. 2009

Research Grants

  1. T Cells, Macrophages, Chemokines, and Adiposopathy in Diet-Induced Obesity
    Christie M Ballantyne; Fiscal Year: 2010
  2. LEUKOCYTE ADHESION MOLECULES AND LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 1999
  3. T Cells, Macrophages, Chemokines, and Adiposopathy in Diet-Induced Obesity
    Christie Ballantyne; Fiscal Year: 2009
  4. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie Ballantyne; Fiscal Year: 2009
  5. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie Ballantyne; Fiscal Year: 2007
  6. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
  7. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2001
  8. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2000
  9. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010

Collaborators

Detail Information

Publications119 found, 100 shown here

  1. ncbi request reprint Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, Texas, USA
    Am J Cardiol 96:14K-19K; discussion 34K-35K. 2005
    ..Clinical trials are needed to determine which treatment strategies provide optimal cardiovascular risk reduction...
  2. pmc LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD
    James McKenney
    National Clinic Research, Inc, Richmond, Virginia, USA
    MedGenMed 7:3. 2005
    ....
  3. pmc A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study
    L Maria Belalcazar
    Department of Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    Diabetes Care 33:2297-303. 2010
    ....
  4. doi request reprint Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study
    Christie M Ballantyne
    Department of Medicine, Baylor College of Medicine and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX, USA Electronic address
    Atherosclerosis 232:86-93. 2014
    ..simvastatin 40 mg and 80 mg plus EZE10 (SIM40/EZE10 and SIM80/EZE10) in patients with coronary heart disease (CHD) or CHD risk equivalent...
  5. doi request reprint Icosapent ethyl for the treatment of hypertriglyceridemia
    Christie M Ballantyne
    Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, 6565 Fannin, M S A 601, Houston, TX 77030, USA
    Expert Opin Pharmacother 14:1409-16. 2013
    ....
  6. ncbi request reprint Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia
    Christie Ballantyne
    Section of Atherosclerosis, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, 6565 Fannin, MS A601, Houston, TX 77030, USA
    J Clin Lipidol 6:235-43. 2012
    ..The use of extended-release niacin and the prostaglandin D₂ receptor antagonist laropiprant (ERN/LRPT) reduces niacin-induced flushing in patients while preserving its lipid-modifying effects...
  7. ncbi request reprint Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)
    Christie M Ballantyne
    Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
    Am J Cardiol 110:984-92. 2012
    ....
  8. pmc Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities study
    Smita I Negi
    Section of Cardiovascular Research, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX, USA
    Diabetes Care 35:1513-8. 2012
    ..However, so far this association has been shown only in predominantly white populations. We examined IL-18 levels and their association with incident DM in a racially heterogeneous population...
  9. doi request reprint Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study
    Christie M Ballantyne
    Baylor College of Medicine, and Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, USA
    Am Heart J 163:515-21, 521.e1-3. 2012
    ..This study analyzed the effect of dalcetrapib on lipoprotein profile, CETP activity, and cellular cholesterol efflux when co-administered with pravastatin in patients with low or average HDL-C...
  10. pmc Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis
    Suet Nee Chen
    Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center and Texas Heart Institute, Houston, TX, USA
    BMC Med Genet 10:111. 2009
    ....
  11. pmc The transcription factor 7-like 2 (TCF7L2) polymorphism may be associated with focal arteriolar narrowing in Caucasians with hypertension or without diabetes: the ARIC Study
    Yu Yan
    Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
    BMC Endocr Disord 10:9. 2010
    ..We therefore aimed to investigate the association between the transcription factor 7-like 2 (TCF7L2) rs7903146 polymorphism and retinal microvascular phenotypes in the Atherosclerosis Risk in Communities (ARIC) Study (1993-1995)...
  12. pmc The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis
    Suet Nee Chen
    Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, and Texas Heart Institute, Houston, TX 77030, USA
    BMC Cardiovasc Disord 9:3. 2009
    ..The LCAS is a randomized placebo-control longitudinal follow-up study in patients with CAD conducted to test the effects of fluvastatin on progression or regression of coronary atherosclerosis...
  13. ncbi request reprint Markers of inflammation and their clinical significance
    Christie M Ballantyne
    Section of Atherosclerosis and Lipoprotein Research, Baylor College of Medicine, 6565 Fannin, M S A 601, Houston, TX 77030 3498, USA
    Atheroscler Suppl 6:21-9. 2005
    ....
  14. ncbi request reprint Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial
    Christie M Ballantyne
    Methodist DeBakey Heart Center, Houston, Texas, USA
    Clin Ther 26:1855-64. 2004
    ..Patients with severe hypercholesterolemia may need greater cholesterol reductions than can be achieved with statin therapy alone...
  15. ncbi request reprint Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia
    C M Ballantyne
    Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, TX 77030, USA
    Int J Clin Pract 58:653-8. 2004
    ..More EZE + ATV patients achieved LDL-C goal than ATV patients at study endpoint (91 vs. 78%, respectively; p = 0.02). Thus, the coadministration of EZE + ATV for 12 months was well tolerated and more efficacious than ATV monotherapy...
  16. ncbi request reprint Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study
    Christie M Ballantyne
    Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, Tex 77030, USA
    Arch Intern Med 165:2479-84. 2005
    ..We assessed Lp-PLA2 and C-reactive protein (CRP) levels along with traditional risk factors to examine their relation to ischemic stroke...
  17. pmc Cholesterol, lipids, and statins
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Texas, USA
    Tex Heart Inst J 32:378-9. 2005
    ..An exciting area for potentially even greater reduction in events is raising HDL-C in conjunction with aggressive efforts to lower LDL-C...
  18. ncbi request reprint Risk for myopathy with statin therapy in high-risk patients
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Baylor College of Medicine, 6565 Fannin, Mail Station A601, Suite A656, Houston, TX 77030, USA
    Arch Intern Med 163:553-64. 2003
    ..Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease...
  19. ncbi request reprint Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II
    Christie M Ballantyne
    Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, TX, USA
    Am Heart J 151:975.e1-9. 2006
    ..This target can be difficult to attain with diet and current therapy...
  20. ncbi request reprint Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)
    Christie M Ballantyne
    Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 99:673-80. 2007
    ..In conclusion, rosuvastatin plus ezetimibe may improve the management of high-risk patients who cannot achieve goal on maximal statin monotherapy...
  21. ncbi request reprint Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends?
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Crit Pathw Cardiol 6:41-5. 2007
    ..More effective management of patients with metabolic syndrome to prevent diabetes and cardiovascular disease will require more effective therapies that target the underlying cause...
  22. ncbi request reprint Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cornerstone 8:S6-13. 2007
    ..Weight loss has also been shown to improve risk factors associated with metabolic syndrome...
  23. pmc Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study
    Salim S Virani
    Michael E DeBakey Veterans Affairs Medical Center Health Services Research and Development Center of Excellence, Houston, TX, USA
    Circulation 125:241-9. 2012
    ..We evaluated associations between Lp(a) and incident CVD events in blacks and whites in the Atherosclerosis Risk in Communities (ARIC) study...
  24. doi request reprint Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu
    Christie M Ballantyne
    Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX 70030, USA
    J Clin Lipidol 5:401-7. 2011
    ..Combination therapy with a statin and a fibrate may be more effective than statin monotherapy for reducing hsCRP, especially in patients with mixed dyslipidemia...
  25. pmc Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides
    Christie M Ballantyne
    Baylor College of Medicine, Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, USA
    Cardiovasc Drugs Ther 25:59-67. 2011
    ..The objective of this study was to evaluate the long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients at goal for low-density lipoprotein cholesterol (LDL-C) but with persistent hypertriglyceridemia...
  26. doi request reprint Strategies for optimizing lipid management
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, TX 77030, USA
    Postgrad Med 116:13-20. 2004
    ..Identification of optimal lipid targets and increased efforts to achieve those targets may help reduce the cardiovascular risk that remains despite lipid-lowering therapy that is currently considered adequate or even aggressive...
  27. pmc Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study
    Vijay Nambi
    Department of Medicine, Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Stroke 40:376-81. 2009
    ....
  28. doi request reprint Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)
    Christie M Ballantyne
    Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
    Am J Cardiol 101:1428-36. 2008
    ..In conclusion, this study showed that NER/S provided additional clinically relevant improvements in multiple lipid parameters and was safe and well tolerated...
  29. doi request reprint Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study
    C M Ballantyne
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Int J Obes (Lond) 32:S21-4. 2008
    ..Several analyses from the Atherosclerosis Risk in Communities (ARIC) study have been performed to examine the role of the metabolic syndrome and its components in predicting risk for cardiovascular disease and diabetes...
  30. doi request reprint Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden
    Christie M Ballantyne
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, Tex 77030, USA
    Circulation 117:2458-66. 2008
    ..Intravascular ultrasound showed atheroma volume regression in a single coronary artery with <50% angiographic luminal narrowing...
  31. ncbi request reprint Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction
    Christie M Ballantyne
    aBaylor College of Medicine and the Methodist DeBakey Heart Center, Houston, Tex 77030, USA
    Am Heart J 148:S3-8. 2004
    ..More effective lipid-lowering therapy than that currently practiced may be needed in many patients to achieve optimal CHD risk reduction...
  32. ncbi request reprint Fluvastatin reduces cardiac mortality in patients with coronary heart disease
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Cardiovasc Drugs Ther 18:67-75. 2004
    ..To test the effectiveness of fluvastatin, 40-80 mg, in reducing the occurrence of cardiac and all-cause mortality in patients with coronary heart disease (CHD)...
  33. ncbi request reprint Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study
    Christie M Ballantyne
    Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and Methodist DeBakey Heart Center, Houston, Tex 77030, USA
    Circulation 109:837-42. 2004
    ..Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a proinflammatory enzyme associated primarily with LDL...
  34. ncbi request reprint Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy
    C M Ballantyne
    Baylor College of Medicine, Houston, Tex 77030, USA
    Circulation 99:736-43. 1999
    ..CONCLUSIONS--Although the predominant lipid-modifying effect of fluvastatin is to decrease LDL-C, patients with low HDL-C received the greatest angiographic and clinical benefit...
  35. ncbi request reprint Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial
    Christie M Ballantyne
    Baylor College of Medicine, 6565 Fannin Street, MS A 601, Houston, Tex 77030, USA
    Circulation 107:2409-15. 2003
    ..Contributing factors may be inadequate dosing, increased risk for adverse effects with high-dose monotherapy, and increased potential for intolerance and adverse effects with combinations of available agents...
  36. ncbi request reprint Role of lipid and lipoprotein profiles in risk assessment and therapy
    Christie M Ballantyne
    Section of Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, Tex 77030, USA
    Am Heart J 146:227-33. 2003
    ..Therapies with beneficial effects across the lipid profile would be expected to improve CHD risk reduction...
  37. ncbi request reprint Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia
    C M Ballantyne
    Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 86:759-63. 2000
    ..Fluvastatin ER was well tolerated. Thus, the new ER formulation of fluvastatin was effective and well tolerated in the once-daily treatment of primary hypercholesterolemia...
  38. ncbi request reprint Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy
    C M Ballantyne
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    J Am Coll Cardiol 36:1572-8. 2000
    ....
  39. ncbi request reprint Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis
    C M Ballantyne
    Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Ther 23:177-92. 2001
    ..Fluvastatin delivery to the liver in a slower but sustained fashion would be expected to avoid hepatic saturation without elevating systemic drug levels...
  40. ncbi request reprint Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 92:3K-9K. 2003
    ..New statins, such as rosuvastatin, offer the prospect of improved lipid-lowering therapy...
  41. ncbi request reprint Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS)
    Christie M Ballantyne
    Baylor College of Medicine, Houston, Tex 77030, USA
    Am Heart J 146:862-9. 2003
    ..Previous studies have shown that effects on high-density lipoprotein cholesterol (HDL-C) may differ among statins...
  42. ncbi request reprint Treating mixed dyslipidemias: why and how
    C M Ballantyne
    Section of Atherosclerosis, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cardiol 24:II-6-9. 2001
    ..Combination therapy with a statin plus either a fibrate or niacin is effective in improving the entire lipid profile, but may increase cost and side effects...
  43. ncbi request reprint Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels
    C M Ballantyne
    Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 88:265-9. 2001
    ....
  44. ncbi request reprint Newer risk markers and surrogate endpoints in atherosclerosis management
    C M Ballantyne
    Atherosclerosis Section, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cardiol 24:III13-7. 2001
    ....
  45. ncbi request reprint Role of selective cholesterol absorption inhibition in the management of dyslipidemia
    Christie M Ballantyne
    Department of Medicine, Baylor College of Medicine, 6565 Fannin Street, MS A 601, Suite A656B, Houston, TX 77030, USA
    Curr Atheroscler Rep 6:52-9. 2004
    ..Ezetimibe is an effective treatment option that may enable more patients with hypercholesterolemia to achieve optimal cholesterol levels and reduce their risk for coronary heart disease...
  46. ncbi request reprint Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome
    Christie M Ballantyne
    Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 91:25C-27C; discussion 28C. 2003
    ..Among patients who met the metabolic syndrome criteria and who had triglycerides > or =200 mg/dL, 64% met their ATP III non-HDL goals...
  47. ncbi request reprint Effects of lipid lowering therapy on progression of coronary and carotid artery disease
    C M Ballantyne
    Baylor College of Medicine, Houston, Texas 77030, USA
    Curr Opin Lipidol 8:354-61. 1997
    ..Angiographic and arterial ultrasound trials of lipid lowering therapy have demonstrated benefits on disease progression that are consistent with benefits on myocardial infarction, stroke, and death reported in larger, lengthier trials...
  48. pmc Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes
    Salman Waheed
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Clin J Am Soc Nephrol 8:434-42. 2013
    ..Combining multiple kidney markers to predict risk is an area of substantial interest...
  49. ncbi request reprint From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II
    Morteza Naghavi
    The Center for Vulnerable Plaque Research, University of Texas Houston, The Texas Heart Institute, and President Bush Center for Cardiovascular Health, Memorial Hermann Hospital, Houston, USA
    Circulation 108:1772-8. 2003
    ..We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients...
  50. ncbi request reprint P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study
    Kelly A Volcik
    Human Genetics Center, University of Texas Houston Health Science Center, 1200 Herman Pressler Dr, Houston, TX 77030, USA
    Atherosclerosis 186:74-9. 2006
    ....
  51. pmc A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis
    Suet N Chen
    Section of Cardiology, Center for Preventive Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    J Am Coll Cardiol 45:1611-9. 2005
    ....
  52. ncbi request reprint Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvas
    Christie M Ballantyne
    Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, Texas 77030, USA
    J Am Coll Cardiol 52:626-32. 2008
    ..The purpose of this analysis was to compare concentrations of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apoB) before and during statin therapy...
  53. ncbi request reprint Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia
    Christie M Ballantyne
    Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 93:1487-94. 2004
    ..5%; p <0.001). All treatments were well tolerated. Thus, a greater LDL cholesterol decrease and HDL cholesterol increase were attained by treating patients with co-administration of ezetimibe and simvastatin than with atorvastatin...
  54. pmc APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels
    Kathy Klos
    Human Genetic Center, University of Texas Health Science Center at Houston, Houston, TX 77225, USA
    Hum Mol Genet 17:2039-46. 2008
    ....
  55. pmc Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin
    Lorraine Salek
    Section of Cardiology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Mol Med (Berl) 80:737-44. 2002
    ..There were no significant interactions between SCAP genotypes and response to therapy. Thus we detected a strong graded interaction between SREBF-1a -36del/G genotypes and response of plasma apoA-I to treatment with fluvastatin...
  56. ncbi request reprint Combination therapy for combined dyslipidemia
    Antonios M Xydakis
    Division of Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 90:21K-29K. 2002
    ..Clinical trials are needed to determine the optimal treatment in patients with combined dyslipidemia...
  57. pmc Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort
    Marco Campos
    Section of Cardiology, Baylor College of Medicine, Houston, TX, USA
    Blood 117:5224-30. 2011
    ..In summary, we identified a cluster of intronic VWF SNPs that associate with plasma levels of VWF, individually or additively, in a large cohort of healthy subjects...
  58. ncbi request reprint Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus
    LaDale St Clair
    Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 99:80B-88B. 2007
    ....
  59. ncbi request reprint LPL polymorphism predicts stroke risk in men
    Alanna C Morrison
    Human Genetics Center, University of Texas Houston Health Science Center, Houston, Texas 77030, USA
    Genet Epidemiol 22:233-42. 2002
    ..This association does not appear to be mediated by triglyceride, high-density lipoprotein (HDL)- and low-density lipoprotein (LDL)-cholesterol levels, or additional stroke risk factors...
  60. ncbi request reprint Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants
    Kelly A Volcik
    Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
    Am J Epidemiol 164:342-8. 2006
    ..The ApoE epsilon2 and epsilon4 alleles were associated with carotid IMT measures in both racial groups, but, after adjusting for lipid parameters, only the epsilon4 allele was associated with carotid IMT measures in African Americans...
  61. ncbi request reprint Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging
    Gareth J Adams
    Structural and Computational Biology and Molecular Biophysics Program, Baylor College of Medicine, Houston, TX, USA
    Magn Reson Imaging 22:1249-58. 2004
    ..This study was designed to determine if regression or progression of human carotid atherosclerosis in patients receiving statin therapy over 24 months can be detected by high-resolution MRI...
  62. ncbi request reprint Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study
    Suetnee Chen
    Sections of Cardiology and Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Pharmacogenetics 14:61-71. 2004
    ..PPARD and PPARG haplotypes are independent determinants of plasma levels of lipids, severity of coronary atherosclerosis and its response to therapy...
  63. ncbi request reprint Lipids and CVD management: towards a global consensus
    Christie Ballantyne
    Arteriosclerosis and Lipoprotein Section, Baylor College of Medicine, Houston, TX, USA
    Eur Heart J 26:2224-31. 2005
    ..It also highlights areas where the guidelines differ and discusses points to consider when selecting the most appropriate recommendation...
  64. pmc Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study
    John W Gaubatz
    Department of Medicine, Baylor College of Medicine, 6565 Fannin St, Houston, TX 77030, USA
    Arterioscler Thromb Vasc Biol 30:1034-42. 2010
    ....
  65. ncbi request reprint Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system
    Mine Y Liu
    Section of Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Chem 51:1102-9. 2005
    ..This study focuses on multiplexed analyses of adipocytokines and biomarkers linked to the metabolic syndrome, diabetes, and cardiovascular disease...
  66. ncbi request reprint Cardiometabolic risk assessment: an approach to the prevention of cardiovascular disease and diabetes mellitus
    Abu R Vasudevan
    Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cornerstone 7:7-16. 2005
    ....
  67. pmc CD11c expression in adipose tissue and blood and its role in diet-induced obesity
    Huaizhu Wu
    Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Tex 77030, USA
    Arterioscler Thromb Vasc Biol 30:186-92. 2010
    ..To examine CD11c, a beta(2)-integrin, on adipose tissue (AT) leukocytes and blood monocytes and its role in diet-induced obesity...
  68. ncbi request reprint Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study
    Christie M Ballantyne
    Department of Medicine, Baylor College of Medicine, Houston, Tex, USA
    Am Heart J 149:464-73. 2005
    ..This study tested the hypothesis that ezetimibe/simvastatin, a lipid-lowering agent that inhibits both intestinal cholesterol absorption and cholesterol synthesis, provides greater LDL-C reductions than atorvastatin across dose ranges...
  69. ncbi request reprint Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management
    Alan B Lumsden
    Methodist DeBakey Heart Center, Baylor College of Medicine, 1709 Dryden Street, Suite 1500, Houston, Texas 77030, USA
    World J Surg 31:695-704. 2007
    ..These studies will advance our understanding of the molecular mechanisms of inflammation and thrombosis associated with aggressive lipid modification...
  70. pmc Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study
    Ariel Brautbar
    Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
    Circ Cardiovasc Genet 2:279-85. 2009
    ....
  71. ncbi request reprint Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk
    Vijay Nambi
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Curr Atheroscler Rep 7:22-8. 2005
    ..The utility of CRP as a target of therapy remains to be proved, and these ongoing studies will likely provide us with guidance...
  72. ncbi request reprint Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction
    Antonios M Xydakis
    Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 89:2697-703. 2004
    ..Thus, increases in plasma levels of adiponectin or reductions in TNF-alpha are not required for marked improvements in glucose/insulin and lipid metabolism with acute weight loss...
  73. pmc Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism
    Ke Ma
    Section of Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine and Methodist Hospital, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 100:2748-53. 2003
    ..We conclude that EL is a major determinant of HDL concentration, structure, and metabolism in mice, and a major determinant of HDL concentration in humans...
  74. ncbi request reprint Role of biomarkers in developing new therapies for vascular disease
    Vijay Nambi
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, 6565 Fannin, M S A 601, Houston, Texas 77030, USA
    World J Surg 31:676-81. 2007
    ..These biomarkers may be used to identify specific populations that may benefit from therapies, as surrogate markers of clinical efficacy, or as targets of therapy...
  75. ncbi request reprint Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study
    Shun Kohsaka
    Texas Heart Institute, Baylor College of Medicine, Houston, TX, United States
    Atherosclerosis 196:926-30. 2008
    ..The present study explored whether the COX-2 G-765C polymorphism contributes to increased incidence of coronary heart disease (CHD) or stroke in the large prospective Atherosclerosis Risk in Communities (ARIC) Study...
  76. pmc Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study
    Salman Waheed
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Am J Kidney Dis 60:207-16. 2012
    ....
  77. pmc Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD)
    Vijay Nambi
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Platelets 20:199-205. 2009
    ..Although the mechanism for these observed differences are not clear, we hypothesize that in vivo platelet activation in PAD patients may contribute to the differences and will need to be further investigated...
  78. ncbi request reprint ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients
    Vijay Nambi
    Department of Medicine, Baylor College of Medicine, 6565 Fannin, MS A 601, Houston, TX 77030, USA
    Curr Atheroscler Rep 6:353-8. 2004
    ..These results suggest that all hypertensive patients with additional risk factors should receive lipid-regulating statin therapy to prevent CAD events...
  79. pmc Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study
    Kelly A Volcik
    Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
    Am J Clin Nutr 87:1926-31. 2008
    ..The binding of polyunsaturated fatty acids (PUFAs) to PPARA results in rapid changes in the expression of genes involved in lipid oxidation, with long-chain n-3 fatty acids being potent activators of PPARA...
  80. pmc Inflammatory protein levels and depression screening after coronary stenting predict major adverse coronary events
    Lorraine Frazier
    School of Nursing, Texas Heart Institute at St Luke s Episcopal Hospital, Houston, Texas 77030, USA
    Biol Res Nurs 11:163-73. 2009
    ..We examined levels of inflammatory proteins to be possible predictors of future MACE and physiological and psychological factors that initiate temporal increases in inflammatory protein levels...
  81. pmc Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study
    Vijay Nambi
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Tex Heart Inst J 35:388-94. 2008
    ....
  82. ncbi request reprint Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients
    Joel D Morrisett
    The Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    J Lipid Res 43:1170-80. 2002
    ....
  83. ncbi request reprint Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events
    Vijay Nambi
    Section of Cardiology, Baylor College of Medicine, 6550 Fannin, SM 677, Houston, TX 77030, USA
    Curr Atheroscler Rep 8:374-81. 2006
    ..Statin therapy has been shown to reduce Lp-PLA(2), and selective inhibitors of Lp-PLA(2) are under development. Additional research is needed to further determine the role of Lp-PLA(2) in atherogenesis and atherothrombotic events...
  84. ncbi request reprint Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription
    Chu Huang Chen
    MS A 601, Department of Medicine, Baylor College of Medicine, 6565 Fannin St, Houston, Texas 77030, USA
    Circulation 107:2102-8. 2003
    ..Apoptosis of vascular endothelial cells (ECs) can be induced in vitro by experimentally modified LDL. Description of proapoptotic circulating lipoproteins may significantly enhance understanding of atherothrombosis pathophysiology...
  85. ncbi request reprint Extra domain A and type III connecting segment of fibronectin in assembly and cleavage
    Yasunori Abe
    Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, USA
    Biochem Biophys Res Commun 338:1640-7. 2005
    ....
  86. pmc Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study
    Kelly A Volcik
    Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, United States
    Atherosclerosis 195:e76-82. 2007
    ..We also tested common haplotypes in the PSEL and PSGL-1 genes to assess associations with incident CHD and ischemic stroke...
  87. pmc Intercellular Adhesion Molecule-1 G241R Polymorphism Predicts Risk of Incident Ischemic Stroke: Atherosclerosis Risk in Communities Study
    Kelly A Volcik
    Human Genetics Center, University of Texas Houston Health Science Center, 1200 Herman Pressler Dr, Houston, TX 77030
    Stroke 41:1038-40. 2010
    ..05) and blacks (hazard rate ratio=7.04; 95% CI, 3.72 to 13.3; P<0.001). CONCLUSIONS: The intercellular adhesion molecule-1 241RR genotype is associated with an increased risk of incident ischemic stroke in both whites and blacks...
  88. ncbi request reprint Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials
    Antonios M Xydakis
    Division of Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Curr Opin Cardiol 18:503-9. 2003
    ..In the third Adult Treatment Panel guidelines of the US National Cholesterol Education Program, non-high-density lipoprotein cholesterol was introduced as a secondary target of therapy in persons with high triglyceride levels...
  89. ncbi request reprint How to identify patients with vulnerable plaques
    Salim S Virani
    Section of Cardiology, Baylor College of Medicine and Texas Heart Institute, St Luke s Episcopal Hospital, Houston, TX, USA
    Diabetes Obes Metab 10:824-33. 2008
    ....
  90. pmc Relationship of alcohol consumption and type of alcoholic beverage consumed with plasma lipid levels: differences between Whites and African Americans of the ARIC study
    Kelly A Volcik
    Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
    Ann Epidemiol 18:101-7. 2008
    ..The influence of different types of alcoholic beverages on plasma lipid levels has been investigated to a lesser extent and in limited populations...
  91. pmc Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study
    Vijay Nambi
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    J Am Coll Cardiol 55:1600-7. 2010
    ..We evaluated whether carotid intima-media thickness (CIMT) and the presence or absence of plaque improved coronary heart disease (CHD) risk prediction when added to traditional risk factors (TRF)...
  92. ncbi request reprint Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trial
    Michael Fordis
    Center for Collaborative and Interactive Technologies, Department of Pediatrics, Baylor College of Medicine, Houston, Tex 77030, USA
    JAMA 294:1043-51. 2005
    ....
  93. ncbi request reprint From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I
    Morteza Naghavi
    The Center for Vulnerable Plaque Research, University of Texas Houston, The Texas Heart Institute, and President Bush Center for Cardiovascular Health, Memorial Hermann Hospital, Houston, USA
    Circulation 108:1664-72. 2003
    ..We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients...
  94. pmc Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels
    Maja Barbalic
    Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA
    Hum Mol Genet 19:1863-72. 2010
    ..These results provide new insights into adhesion molecule biology...
  95. ncbi request reprint Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome
    Henry D Huang
    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States
    Int J Cardiol 168:3741-6. 2013
    ..It is unclear whether its benefits exist in patients with ACS and advanced chronic kidney disease (CKD), because these patients are often sub-optimally treated and excluded from clinical trials...
  96. ncbi request reprint Endothelial lipase and cholesterol metabolism
    Mehmet Cilingiroglu
    Section of Cardiology and Atherosclerosis, Baylor College of Medicine, One Baylor Plaza, Jewish Building 519 D, Houston, TX 77030, USA
    Curr Atheroscler Rep 6:126-30. 2004
    ..The expression is highly regulated by cytokines and physical forces. These data suggest that EL may play a significant role in atherosclerosis...
  97. pmc Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study
    Justin T Saunders
    6565 Fannin, MS A 601, Houston, TX 77030, USA
    Circulation 123:1367-76. 2011
    ....
  98. ncbi request reprint Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II)
    Prakash C Deedwania
    University of California San Francisco, School of Medicine, Fresno, CA 93703, USA
    J Cardiometab Syndr 1:295-300. 2006
    ..The metabolic syndrome is common in patients receiving lipid-lowering therapy in an office-based setting. Three recent definitions resulted in similar estimates of its prevalence...
  99. ncbi request reprint Apolipoprotein E genotype and incident ischemic stroke: the Atherosclerosis Risk in Communities Study
    Jared D Sturgeon
    Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA
    Stroke 36:2484-6. 2005
    ..A relationship between the apolipoprotein E (apoE) genotype and ischemic stroke has been inconsistently reported. We explored this relation in the Atherosclerosis Risk in Communities Study (ARIC)...
  100. ncbi request reprint The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study
    Ann Marie McNeill
    University of North Carolina, Chapel Hill, 137 E Franklin St, Chapel Hill, NC 28514, USA
    Diabetes Care 28:385-90. 2005
    ..To assess the magnitude of the association between the National Cholesterol Education Program's Third Adult Treatment Panel Report (ATP III) definition of the metabolic syndrome and cardiovascular disease (CVD)...

Research Grants11

  1. T Cells, Macrophages, Chemokines, and Adiposopathy in Diet-Induced Obesity
    Christie M Ballantyne; Fiscal Year: 2010
    ..To test our hypothesis, we will study the effects of diet-induced obesity on a number of factors related to inflammation in mice and also in human fat cells. ..
  2. LEUKOCYTE ADHESION MOLECULES AND LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 1999
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  3. T Cells, Macrophages, Chemokines, and Adiposopathy in Diet-Induced Obesity
    Christie Ballantyne; Fiscal Year: 2009
    ..To test our hypothesis, we will study the effects of diet-induced obesity on a number of factors related to inflammation in mice and also in human fat cells. ..
  4. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie Ballantyne; Fiscal Year: 2009
    ....
  5. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie Ballantyne; Fiscal Year: 2007
    ....
  6. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  7. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2001
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  8. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2000
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  9. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
    ....